Monoclonal antibodies in frontline acute lymphoblastic leukemia

被引：5

作者：

Chew, Serena ^{[1
]}

Jammal, Nadya ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Jabbour, Elias ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Box 428, Houston, TX 77030 USA

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2020年 / 33卷 / 04期

关键词：

Acute lymphoblastic leukemia; ALL; Monoclonal antibodies; Adult; Frontline; ACUTE LYMPHOCYTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; INOTUZUMAB OZOGAMICIN; ADULT BURKITT; HYPER-CVAD; SINGLE-ARM; PHASE-II; BLINATUMOMAB; RITUXIMAB; THERAPY;

D O I：

10.1016/j.beha.2020.101226

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The recent development of monoclonal antibodies targeting CD19, CD20, and CD22 has significantly improved long-term survival in patients with acute lymphoblastic leukemia (ALL), both in the frontline and relapsed and refractory setting. The incorporation of CD20 monoclonal antibodies (e.g. rituximab) has improved cure rates from 35% to 50% in those with precursor B-cell ALL and from 40 to 80% in those with Burkitt leukemia. More novel antibodies, such as drug conjugates antibodies (e.g. inotuzumab ozogamicin) and bispecific T-cell engagers (e.g. blinatumomab), have shown significant promise in improving outcomes in the relapsed and refractory setting and are currently being studied in the frontline setting, with hopes to further improve long-term outcomes. In this chapter, we will review the role of monoclonal antibodies and how the incorporation of these agents has revolutionized and changed the treatment management of ALL in the frontline setting.

引用

页数：8

共 49 条

[11]

Gokbuget Nicola, 2006, Hematology Am Soc Hematol Educ Program, P133

[12] Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia [J].

Guerra, Veronica A. ;

Jabbour, Elias J. ;

Ravandi, Farhad ;

Kantarjian, Hagop ;

Short, Nicholas J. .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10 :1-17

[13] Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis [J].

Herold, Tobias ;

Schneider, Stephanie ;

Metzeler, Klaus H. ;

Neumann, Martin ;

Hartmann, Luise ;

Roberts, Kathryn G. ;

Konstandin, Nikola P. ;

Greif, Philipp A. ;

Braeundl, Kathrin ;

Ksienzyk, Bianka ;

Huk, Natalia ;

Schneider, Irene ;

Zellmeier, Evelyn ;

Jurinovic, Vindi ;

Mansmann, Ulrich ;

Hiddemann, Wolfgang ;

Mullighan, Charles G. ;

Bohlander, Stefan K. ;

Spiekermann, Karsten ;

Hoelzer, Dieter ;

Bruggemann, Monika ;

Baldus, Claudia D. ;

Dreyling, Martin ;

Goekbuget, Nicola .

HAEMATOLOGICA, 2017, 102 (01) :130-138

[14] Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial [J].

Hoelzer, Dieter ;

Walewski, Jan ;

Doehner, Hartmut ;

Viardot, Andreas ;

Hiddemann, Wolfgang ;

Spiekermann, Karsten ;

Serve, Hubert ;

Duehrsen, Ulrich ;

Huettmann, Andreas ;

Thiel, Eckhard ;

Dengler, Jolanta ;

Kneba, Michael ;

Schaich, Markus ;

Schmidt-Wolf, Ingo G. H. ;

Beck, Joachim ;

Hertenstein, Bernd ;

Reichle, Albrecht ;

Domanska-Czyz, Katarzyna ;

Fietkau, Rainer ;

Horst, Heinz-August ;

Rieder, Harald ;

Schwartz, Stefan ;

Burmeister, Thomas ;

Goekbuget, Nicola .

BLOOD, 2014, 124 (26) :3870-3879

[15] Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+B-Lineage Standard and High Risk Patients; Results of 263 CD20+Patients Studied Prospectively In GMALL Study 07/2003 [J].

Hoelzer, Dieter ;

Huettmann, Andreas ;

Kaul, Felix ;

Irmer, Sebastian ;

Jaekel, Nadja ;

Mohren, Martin ;

Lipp, Thomas ;

Wedelin, Knut ;

de Valle, Francisco ;

Schmid, Mathias ;

Thiel, Eckhard ;

Brueggemann, Monika ;

Kneba, Michael ;

Goekbuget, Nicola .

BLOOD, 2010, 116 (21) :77-78

[16]

Jabbour E, 2020, LANCET HAEMATOL, V7, pE523, DOI 10.1016/S2352-3026(20)30144-7

[17] Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage [J].

Jabbour, Elias ;

Sasaki, Koji ;

Ravandi, Farhad ;

Huang, Xuelin ;

Short, Nicholas J. ;

Khouri, Maria ;

Kebriaei, Partow ;

Burger, Jan ;

Khoury, Joseph ;

Jorgensen, Jeffrey ;

Jain, Nitin ;

Konopleva, Marina ;

Garcia-Manero, Guillermo ;

Kadia, Tapan ;

Cortes, Jorge ;

Jacob, Jovitta ;

Montalbano, Kathryn ;

Garris, Rebecca ;

O'Brien, Susan ;

Kantarjian, Hagop M. .

CANCER, 2018, 124 (20) :4044-4055

[18] Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial [J].

Jabbour, Elias ;

Ravandi, Farhad ;

Kebriaei, Partow ;

Huang, Xuelin ;

Short, Nicholas J. ;

Thomas, Deborah ;

Sasaki, Koji ;

Rytting, Michael ;

Jain, Nitin ;

Konopleva, Marina ;

Garcia-Manero, Guillermo ;

Champlin, Richard ;

Marin, David ;

Kadia, Tapan ;

Cortes, Jorge ;

Estrov, Zeev ;

Takahashi, Koichi ;

Patel, Yogin ;

Khouri, Maria R. ;

Jacob, Jovitta ;

Garris, Rebecca ;

O'Brien, Susan ;

Kantarjian, Hagop .

JAMA ONCOLOGY, 2018, 4 (02) :230-234

[19] Monoclonal antibodies in acute lymphoblastic leukemia [J].

Jabbour, Elias ;

O'Brien, Susan ;

Ravandi, Farhad ;

Kantarjian, Hagop .

BLOOD, 2015, 125 (26) :4010-4016

[20] Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody [J].

Jabbour, Elias ;

O'Brien, Susan ;

Huang, Xuelin ;

Thomas, Deborah ;

Rytting, Michael ;

Sasaki, Koji ;

Cortes, Jorge ;

Garcia-Manero, Guillermo ;

Kadia, Tapan ;

Ravandi, Farhad ;

Pierce, Sherry ;

Kantarjian, Hagop .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (03) :193-196

← 1 2 3 4 5 →